PPARD and metabolic syndrome: PPAR alpha and gamma agonists have been used for the clinical treatment of dyslipidemia and diabetes [2], whereas PPARβ/δ agonists have been controversial due to concerns about their pro-inflammatory and pro-tumorigenesis effects in vitro [3].